Wave Life Sciences Ltd. announced the appointment of Mark Baldry as Chief Commercial Officer. In this newly created position, Mr. Baldry will build and oversee Wave’s global commercial strategy and organization, including its sales, marketing and market access and reimbursement teams. Initially, he will focus on the launch planning for suvodirsen, the company’s investigational stereopure oligonucleotide intended for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Mr. Baldry joins Wave with almost 30 years of global commercial experience in neuroscience and rare disease and has held positions of increasing responsibility in the United States, Canada, France and the United Kingdom. Most recently, Baldry served as Senior Vice President, Global Marketing & Commercial Operations at Amicus Therapeutics.